Cases & Deals

Invus participates in €20 million investment in Sensorion

Clients Invus

Jones Day advised Invus, as lead investor, alongside with Sofinnova, in the €20 million (US$22.6 million) convertible bonds issue of Sensorion, a clinical-stage biopharmaceutical company, which specializes in the development of novel therapies to restore, treat, and prevent inner ear diseases.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.